US 12,268,882 B2
Beta blocker therapy with electrical administration
Benny Rousso, Rishon-LeZion (IL); Yuval Mika, Closter, NJ (US); Shlomo Ben-Haim, Geneva (CH); and Hani N. Sabbah, Waterford, MI (US)
Assigned to Impulse Dynamics NV, Willemstad (CW)
Filed by Impulse Dynamics NV, Willemstad (CW)
Filed on Oct. 9, 2023, as Appl. No. 18/377,857.
Application 18/377,857 is a continuation of application No. 17/524,015, filed on Nov. 11, 2021, granted, now 11,779,768.
Application 17/524,015 is a continuation of application No. 16/232,088, filed on Dec. 26, 2018, abandoned.
Application 16/232,088 is a continuation of application No. 15/249,506, filed on Aug. 29, 2016, granted, now 10,352,948, issued on Jul. 16, 2019.
Application 15/249,506 is a continuation of application No. 14/641,480, filed on Mar. 9, 2015, granted, now 9,440,080, issued on Sep. 13, 2016.
Application 14/641,480 is a continuation of application No. 13/970,647, filed on Aug. 20, 2013, granted, now 8,977,353, issued on Mar. 10, 2015.
Application 13/970,647 is a continuation of application No. 11/919,491, granted, now 8,548,583, issued on Oct. 1, 2013, previously published as PCT/US2006/017281, filed on May 4, 2006.
Application 11/919,491 is a continuation of application No. PCT/US2005/044557, filed on Dec. 9, 2005.
Application 11/919,491 is a continuation of application No. PCT/IL2006/000204, filed on Feb. 16, 2006.
Claims priority of provisional application 60/634,625, filed on Dec. 9, 2004.
Claims priority of provisional application 60/677,761, filed on May 4, 2005.
Claims priority of provisional application 60/719,517, filed on Sep. 22, 2005.
Prior Publication US 2024/0042214 A1, Feb. 8, 2024
Int. Cl. A61N 1/362 (2006.01); A61N 1/32 (2006.01); A61N 2/00 (2006.01); C12N 13/00 (2006.01); A61N 1/20 (2006.01); C12Q 1/6883 (2018.01); G01N 33/68 (2006.01)
CPC A61N 1/3627 (2013.01) [A61N 1/32 (2013.01); A61N 1/3628 (2013.01); A61N 2/004 (2013.01); C12N 13/00 (2013.01); A61N 1/205 (2013.01); A61N 1/3629 (2017.08); C12Q 1/6883 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/158 (2013.01); G01N 33/6893 (2013.01); G01N 2800/325 (2013.01)] 23 Claims
OG exemplary drawing
 
1. A method of enhancing an effect on LVEF (left ventricle ejection fraction) increase of beta blocker therapy, comprising:
(a) selecting a patient with heart failure where an increase in LVEF beyond that expected for a beta blocker, is desired;
(b) electrically administering a non-excitatory electrical field to the heart with parameters suitable to provide one or more of (i) an acute increase in contractility; (ii) phosphorylation of phospholamban; and (iii) reversing a fetal gene program; and
(c) continuing said electrically administering while pharmaceutically administering beta blockers for a period of at least 3 months to increase the beta blocker therapy effect on LVEF.